← Back to signals
EW
AVOIDEdwards Lifesciences Corporation
Health Care
1.86
PEGY ratio
Rank #350
Why This Matters
This stock appears overvalued relative to its growth and dividend yield. Strong projected growth of 82.0% annually over 5 years.
EW trades at 46.5x earnings against 25.0% capped growth (actual 82.0%) (no dividend) (PEGY 1.86). The valuation appears stretched relative to the available growth and income.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 82.0%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-06-11
Valuation
46.5x
P/E Ratio
Growth
82.0%
5yr EPS
Income
0.0%
Div Yield
PEGY Components
PEGY Score1.86
Denominator25.0%
EPS (TTM)$1.85
Market Data
Price$85.98
ExchangeNYSE
S&P 500
What Changed
PEGY Score
1.86→1.86(-0.00)
Rank
#347→#350(3 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only